Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Effect of high-dose intravenous vitamin C on prognosis in patients with SARS-CoV...
Journal Information
Vol. 158. Issue 8.
Pages 356-360 (April 2022)
Share
Share
Download PDF
More article options
ePub
Visits
8
Vol. 158. Issue 8.
Pages 356-360 (April 2022)
Original article
Effect of high-dose intravenous vitamin C on prognosis in patients with SARS-CoV-2 pneumonia
Efecto de la vitamina C intravenosa en dosis altas sobre el pronóstico en pacientes con neumonía por SARS-CoV-2
Visits
...
Kavurgacı Suna, Uzel Şener Melahat, Yıldız Murat, Öztürk Ergür Figen, Öztürk Ayperi
Corresponding author
drayperi@yahoo.com

Corresponding author.
Health Sciences University Faculty of Medicine Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Interventional Pulmonology Department, Ankara, Turkey
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (2)
Table 1. Baseline characteristics of patients according to given vitamin C.
Table 2. Baseline and post-treatment values.
Show moreShow less
Abstract
Background

Until now, the coronavirus disease 2019 (COVID-19) pandemic has affected more than 2.5 million individuals worldwide, with approximately 170,000 deaths. Currently, no treatments with robust evidence of clinical benefit exist, and utilization of experimental agents have been recommended by national and international guidelines as a part of clinical studies.

Method

In this retrospective study, a total of 323 patients severe acute respiratory syndrome due to PCR-documented COVID-19 infection admitted in our unit were included. Patients were categorized into two groups as those who did or did not receive high dose intravenous vitamin C. we examined the effect of high dose intravenous vitamin C administered in addition to other commonly used agents on prognosis in patients with COVID-19 pneumonia.

Results

As compared to patients who did not receive vitamin C, those in the VC group were not significantly different in terms of the length of hospital stay (p=0.05), re-admission rate (p=0.943), admission to intensive care, need for advanced oxygen support (p=0.488), need for advanced medical treatment (p<0.001), and mortality (p=0.52).

Conclusion

The limited evidence based on small samples precludes definitive conclusions regarding the potential efficacy of high dose vitamin C in these patients, indicating the need for further assessment within the context of clinical research.

Keywords:
COVID-19
Vitamin C
Mortality
Resumen
Antecedentes

Hasta ahora, la pandemia de la enfermedad por coronavirus 2019 (COVID-19) ha afectado a más de 2,5 millones de individuos en todo el mundo, con aproximadamente 170.000 muertes. En la actualidad, no existen tratamientos con evidencias sólidas de beneficio clínico, y la utilización de agentes experimentales ha sido recomendada por las guías nacionales e internacionales como parte de los estudios clínicos.

Método

En este estudio retrospectivo se incluyeron un total de 323 pacientes con síndrome respiratorio agudo severo por infección por COVID-19 documentada por PCR, ingresados en nuestra unidad. Los pacientes se clasificaron en 2 grupos, según recibieran o no dosis elevadas de vitamina C intravenosa. Se examinó el efecto de la administración de dosis elevadas de vitamina C intravenosa, además de otros agentes utilizados habitualmente, sobre el pronóstico de los pacientes con neumonía por COVID-19.

Resultados

En comparación con los pacientes que no recibieron vitamina C, los del grupo que recibieron vitamina C no fueron significativamente diferentes en cuanto a la duración de la estancia hospitalaria (p=0,05), la tasa de reingreso (p=0,943), el ingreso en cuidados intensivos, la necesidad de soporte avanzado de oxígeno (p=0,488), la necesidad de tratamiento médico avanzado (p<0,001) y la mortalidad (p=0,52).

Conclusiones

Las limitadas evidencias basadas en muestras pequeñas impiden sacar conclusiones definitivas sobre la potencial eficacia de la vitamina C en dosis altas en estos pacientes, lo que indica la necesidad de una mayor evaluación en el contexto de la investigación clínica.

Palabras clave:
COVID-19
Vitamina C
Mortalidad

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos